Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Cynthia M. Pruss"'
Autor:
Bruno A. Svajger, Justin L. H. Riddoch, Cynthia M. Pruss, Kimberly J. Laverty, Emilie Ward, Rachel M. Holden, Michael A. Adams
Publikováno v:
Physiological Reports, Vol 8, Iss 21, Pp n/a-n/a (2020)
Abstract The mineral‐bone axis is tightly regulated and dependent on renal function. In chronic kidney disease (CKD) progressive loss of renal capacity disrupts this axis over‐time, with marked changes in circulating calcium, phosphate, PTH, and
Externí odkaz:
https://doaj.org/article/1fa52d5cf2e14faeb374b7a8a1fcdadc
Autor:
Bruno A. Svajger, Cynthia M. Pruss, Kimberly J. Laverty, Jason G. E. Zelt, Glenville Jones, Martin Kaufmann, Martin Petkovich, Rachel M. Holden, Michael A. Adams
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 3, Pp n/a-n/a (2020)
Abstract Vitamin D receptor agonist (VDRA) therapy for PTH suppression is a mainstay for patients with severe CKD. Calcitriol (1,25‐(OH)2D3) is a former first‐line VDRA in CKD treatment. However, a consequence of its use in CKD is accelerated vas
Externí odkaz:
https://doaj.org/article/466b607f685f4fa0b0f553c185125b15
Autor:
Emilie Ward, Kimberly Laverty, Michael A. Adams, Bruno Svajger, Justin L. H. Riddoch, Cynthia M. Pruss, Rachel M. Holden
Publikováno v:
Physiological Reports
Physiological Reports, Vol 8, Iss 21, Pp n/a-n/a (2020)
Physiological Reports, Vol 8, Iss 21, Pp n/a-n/a (2020)
The mineral‐bone axis is tightly regulated and dependent on renal function. In chronic kidney disease (CKD) progressive loss of renal capacity disrupts this axis over‐time, with marked changes in circulating calcium, phosphate, PTH, and fibroblas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d4a51448a624593c7f71e905515d603
http://europepmc.org/articles/PMC7666773
http://europepmc.org/articles/PMC7666773
Autor:
Martin Kaufmann, Cynthia M. Pruss, Bruno Svajger, Rachel M. Holden, Michael A. Adams, Martin Petkovich, Jason G.E. Zelt, Kimberly Laverty, Glenville Jones
Publikováno v:
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives, Vol 8, Iss 3, Pp n/a-n/a (2020)
Pharmacology Research & Perspectives, Vol 8, Iss 3, Pp n/a-n/a (2020)
Vitamin D receptor agonist (VDRA) therapy for PTH suppression is a mainstay for patients with severe CKD. Calcitriol (1,25‐(OH)2D3) is a former first‐line VDRA in CKD treatment. However, a consequence of its use in CKD is accelerated vascular cal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8b9272c119fa87199977dbc4d293646
https://doi.org/10.1002/prp2.605
https://doi.org/10.1002/prp2.605
Autor:
Cynthia M. Pruss, Emilie Ward, Kim Laverty, Michael A. Adams, Bruno Svajger, Rachel M. Holden
Publikováno v:
Nephrology Dialysis Transplantation. 34
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7668de2b5d0a6bace115cfc77ad360e0
https://doi.org/10.1093/ndt/gfz106.fp460
https://doi.org/10.1093/ndt/gfz106.fp460
Autor:
Lok Hang Lee, Mandy E Turner, Michael A. Adams, Cynthia M. Pruss, Kim Laverty, Emilie Ward, Rachel M. Holden
Publikováno v:
The FASEB Journal. 33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92d1d8fe8fb2b852780898c3742e5042
https://doi.org/10.1096/fasebj.2019.33.1_supplement.678.14
https://doi.org/10.1096/fasebj.2019.33.1_supplement.678.14
Autor:
Andrea Bryant, Sandra L. Haberichter, Mia Golder, Kate Sponagle, Cynthia M. Pruss, Kimberly Laverty, Erin Burnett, Colleen Notley, Carol Hegadorn, David Lillicrap, Aly S. Dhala
Publikováno v:
Blood. 117:4358-4366
Type 1 VWD is the mild to moderate reduction of VWF levels. This study examined the mechanisms underlying 2 common type 1 VWD mutations, the severe R1205H and more moderate Y1584C. In vitro biosynthesis was reduced for both mutations in human and mou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecfb378aa6cc3327c1d5e08922993e43
https://doi.org/10.1182/blood-2010-08-303727
https://doi.org/10.1182/blood-2010-08-303727
Autor:
Kimberly Laverty, Kate Sponagle, David Lillicrap, Mia Golder, Cynthia M. Pruss, Jeffrey Mewburn, Carol Hegadorn
Publikováno v:
Blood. 115:4862-4869
Type 2B von Willebrand disease (2B VWD) results from von Willebrand factor (VWF) A1 mutations that enhance VWF-GPIbα binding. These “gain of function” mutations lead to an increased affinity of the mutant VWF for platelets and the binding of mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26370cf026bfabf3ede805db30739025
https://doi.org/10.1182/blood-2009-11-253120
https://doi.org/10.1182/blood-2009-11-253120
Autor:
Cynthia M. Pruss, M. Bowman, D. Rapson, Paula D. James, E. Groot, Peter J. Lenting, J. Stakiw, Colleen Notley, David Lillicrap, Carol Hegadorn
Publikováno v:
ResearcherID
Journal of Thrombosis and Haemostasis, 6(1), 90-96. Wiley
Journal of Thrombosis and Haemostasis, 6(1), 90-96. Wiley
Background: The effect of exercise on von Willebrand factor (VWF) and ADAMTS-13 levels in individuals with von Willebrand disease (VWD) has never been reported. Objectives: The aim was to quantify the effect of a standardized exercise protocol on ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::010321745fa290bdff4c9f37c15312d8
https://doi.org/10.1111/j.1538-7836.2007.02790.x
https://doi.org/10.1111/j.1538-7836.2007.02790.x
Publikováno v:
Journal of Thrombosis and Haemostasis. 5:P-W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8284bb64a26a79a25afc1c10894bc28
https://doi.org/10.1111/j.1538-7836.2007.tb02743.x
https://doi.org/10.1111/j.1538-7836.2007.tb02743.x